6th German Pharm-Tox Summit
87th Annual Meeting of the
German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT)
With contribution of AGAH
1 – 3 March 2021 • Digital
6th German Pharm-Tox Summit
87th Annual Meeting of the
German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT)
With contribution of AGAH
1 – 3 March 2021 • Digital
Advanced Courses - The log-in data to the courses will be send out on Monday, March 1rst, 2021 at 7am.
Date: March 1st, 2021
Applications of genome editing techniques in model systems of Experimental Pharmacology
| 13:00 | Welcome Marc Freichel, Heidelberg and Susanne Lutz, Göttingen |
| 13:15 | How to CRISPR: precise and efficient genome editing Thomas Thumberger, Heidelberg |
| 14:00 | Engineering CRISPR cell lines and mouse models – advances & challenges Rebekka Medert, Heidelberg |
| 14:45 | Break |
| 15:15 | Programming Biology: engineering transcription via CRISPR/Cas9 to control cell behaviour Laura Zelarayan, Göttingen |
| 16:00 | Testing of CRISPR treatments in cardiovascular diseases Lucas Cyganek, Göttingen |
| 16:45 | Final discussion |
Date: March 1st, 2021
| 14:00 | Recognition and prediction of pharmacological effects - non-invasive in-vivo imaging (focus on MRI) Andreas Hess, Erlangen |
| 15:00 | New possibilities for microscopic imaging with confocal microscopes, superresolution STED and Minflux Karsten Bahlmann, Cambridge, MA, USA |
| 16:00 | PET imaging in determination of drug disposition Oliver Langer, Wien |
Computational/in silicoToxicology/QSARs – Implementation and Assessment in the Regulatory Context
Date: March 1st, 2021
| 10:00 | Welcome and Introductory Remarks Michael Werner, Prosacon |
| 10:20 | The use and assessment of QSAR predictions under REACH Andrea Gissi, ECHA |
| 10:55 | Use of QSAR/Read Across for the evaluation of pesticide metabolites and impurities – An industry perspective Markus Frericks, BASF |
| 11:30 | Coffee Break |
| 11:45 | Application of SAR and modelling in pharmaceutical and medical device industry: Secondary pharmacology modelling (e.g. CiPA initiative), Nitrosamines in the context of ICH M7 and implications for risk assessment for Medical Devices Andreas Czich, Sanofi Susanne Dorn, knoell |
| 12:20 | Lunch Break + General Meeting Working Group Regulatory Toxicology |
| 13:45 | Endocrine Disruptors – regulatory use of in silico as part of alternative methods Vera Ritz, BfR |
| 14:20 | How to perform risk assessment of a new cosmetic ingredient using new approach methodologies? - Systemic exposure assessment and SAR based read across applied to oxidative hair dyes Carsten Goebel, Wella Company |
| 14:55 | In Silico Toxicology Protocols – defining standards and best practices towards mutual acceptance of data Glenn Myatt, Leadscope |
| 15:30 | Coffee Break |
| 15:45 | Panel discussion – Challenges in the further application of in silico models and tools Jochen vom Brocke, ECHA Monika Batke, University Emden/Leer All Panellists |